

【Press Release】

29 Apr 2019



## ESSEX BIO-TECHNOLOGY LIMITED 億勝生物科技有限公司

(Stock Code: 1061)

### Essex Bio-Technology Announces Upcoming Joint Presentation with Mitotech and Ora at ARVO 2019 Annual Meeting

Hong Kong, 29 April 2019 -- Essex Bio-Technology Limited ("EssexBio" or the "Group" or the Company, Stock code: 1061) today announced that the Company, Mitotech S.A. ("Mitotech"), a clinical-stage Luxembourg-based biotechnology company developing novel drug targeting mitochondria, together with Ora, Inc. ("Ora"), the world's leading full-service ophthalmology CRO and product development firm, will jointly present the design of Phase 3 clinical trial, VISTA-1, exploring a First-in-Class ophthalmic mitochondrial reactive oxygen (mtROS) scavenger SkQ<sub>1</sub> for the treatment of Dry Eye Disease ("DED"), at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting in Vancouver, Canada.

Details of poster are as follows:

**Abstract Number:** 6750 – B0274

**Section Name:** Cornea Dry Eye Clinical Treatment

**Type:** Poster

**Date:** Thursday, May 2, 2019, 10:15am – 12:00pm PT

**Location:** West Exhibition Hall

## **Data Summary**

SkQ<sub>1</sub> ophthalmic solution is a first-in-class drug designed for protection of ocular surface from oxidative stress at mitochondrial level. In a previous Phase 2 study SkQ<sub>1</sub> showed evidence of efficacy in reducing both the signs and symptoms in dry eye subjects.

## **About VISTA-1**

VISTA-1 is a multi-center, double-masked, randomized, placebo-controlled study comprising 5 visits over the course of approximately 9 weeks. Qualified subjects(n=444) are randomized 1:1:1 to receive either high dose SkQ<sub>1</sub> ophthalmic solution(1.55ug/mL), low dose SkQ<sub>1</sub> ophthalmic solution(0.155ug/mL), or placebo (vehicle of SkQ<sub>1</sub> ophthalmic solution).

## **About ARVO**

The Association for Research in Vision and Ophthalmology, Inc. (ARVO) is the largest and most respected eye and vision research organization in the world. Its members include nearly 12,000 researchers from over 75 countries. ARVO advances research worldwide into understanding the visual system and preventing, treating and curing its disorders. The ARVO 2019 Annual Meeting will have the theme as “From bench to bedside and back”.

## **About Mitotech**

Mitotech S.A. is a clinical-stage Luxembourg-based biotechnology company developing novel drugs for the treatment of predominantly age-related disorders. The core technology behind Mitotech products is based on a novel class of small molecules – mitochondria targeting cardiolipin peroxidation inhibitors. Company's lead compound SkQ<sub>1</sub> is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases. Mitotech successfully completed Phase II clinical study for Dry Eye Disease in the U.S. with other indications also approaching clinical stage of development.

## **About Ora**

Ora is the world's leading full-service ophthalmic CRO and product development firm with offices in the United States, the United Kingdom, Australia and Japan. Over the past 40 years, Ora has proudly helped its clients earn more than 47 product approvals. Ora supports a wide array of organisations, from start-ups to global pharmaceutical and device companies, to efficiently bring new products from concept to market. Ora's pre-clinical and clinical models, unique methodologies and global regulatory strategies have been refined and

proven across thousands of global projects. Ora brings together the world's most extensive and experienced team of ophthalmic experts and R&D professionals to maximise the value of product initiatives.

## About EssexBio

Essex Bio-Technology Limited is a bio-pharmaceutical company, started in early 90's, a pioneer in bio-pharmaceutical industry in China, that develops, manufactures and commercialises genetically engineered therapeutic rb-bFGF, a basic fibroblast growth factor, with established mechanism of action in cellular proliferation, differentiation and migration.

The Company currently has five commercialised bio-pharmaceutical products, formulated with rb-bFGF, in China, out of which 3 are approved by CFDA as Category I drugs. The products are being marketed & sold as Beifushu, Beifuji & Beifuxin, for treatment of ocular surface wounds and topical (skin) surface wounds respectively. Beifuji is the first in the world to have obtained approval from CFDA (now the National Medical Products Administration ("NMPA")) for commercialisation in 1998.

In addition, the Group has three NMPA approved preservative-free, single-dose eye drops: Tobramycin, Levofloxacin and Sodium Hyaluronate.

The Company focuses on two main therapeutics: Ophthalmology and Surgical arena of topical (skin) surface wounds, which primarily covers Dermatology, Stomatology and Obstetrics & Gynaecology, while selectively pursuing therapeutics in Neurology, Oncology and Orthopaedics. The Company maintains a pipeline of multi-project in R&D and on various stages of clinical programs, of which several projects involving growth factors and antibody and a handful of projects are on unit dose for Ophthalmic and Respiratory disease.

The Company's products and its 3rd party products are marketed and sold through more than 6,300 hospitals in China and are managed directly by its 42 regional sales offices with about 1,320 sales and marketing people. Its 3rd party products, notably are inclusive of Xalacom eye drops and Xalatan eye drops of Pfizer (for Ophthalmology), Iodized Lecithin Capsules (for Ophthalmology), Yi Xue An Granules (for Obstetrics & Gynaecology).

Zhixin Investor Relations Consultant issued this press release on behalf of **Essex Bio-Technology Limited**.

For further information, please contact:

Zhixin Investor Relations Consultant Limited

Ms. Lin Xiaoyan

Tel: +86 (755) 8323 9767

E-mail: [Linxiaoyan@zhixincaijing.com](mailto:Linxiaoyan@zhixincaijing.com)